ScreenerHero

TENXTenax Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tenaxthera.com
1.750USD-7.89%Mkt Cap: 65.49M $P/E: —

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap65.49M $
Enterprise Value-16.01M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-52.60M $
Revenue/Share—
Last Price1.750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS88032L5066
Valuation
P/E (Trailing)—
P/E (Forward)-1.19
PEG1.44
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.78
EPS (TTM)-1.38
EPS (Forward)-1.50
52W Range
1.3102% of range19.40
52W High19.40 USD
52W Low1.310 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.19%
ROA-50.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.80M $
CapEx (TTM)—
FCF Margin—
FCF Yield-36.72%
Net Debt-117.98M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio15.07
Quick Ratio14.61
Book Value/Sh2.288 USD
Cash/Share2.060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 26, 2018
Splits
Last Split1:80
Split DateJan 3, 2024
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.70 USD
Upside (mean)+568.6%
Target Range4.000 USD – 36.00 USD
$4.000+568.6% to mean$36.00
# Analysts10
Ownership
Shares Out.37.42M
Float37.37M
Insiders0.11%
Institutions88.06%
Short Interest
Short Ratio1.8d
Short % Float6.89%
Short % Out.6.83%
Shares Short2.56M
Short (prev mo.)1.79M
Technical
SMA 5012.02 (-85.4%)
SMA 20012.16 (-85.6%)
Beta0.93
S&P 52W Chg18.16%
Avg Vol (30d)5.99M
Avg Vol (10d)16.88M
Technical Indicators
RSI (14)20.1
MACD-3.5469
MACD Signal-2.5660
MACD Hist.-0.9809
BB Upper22.16 USD
BB Middle9.322 USD
BB Lower-3.5151 USD
BB Width275.42%
ATR (14)1.260 USD
Vol Ratio (20d)0.50x